Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) Enterprise Value: 2018-2025

Historic Enterprise Value for Bicycle Therapeutics (BCYC) over the last 8 years, with Sep 2025 value amounting to -$111.9 million.

  • Bicycle Therapeutics' Enterprise Value fell 116.69% to -$111.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.5 billion, marking a year-over-year decrease of 96.65%. This contributed to the annual value of $87.1 million for FY2024, which is 63.78% down from last year.
  • Latest data reveals that Bicycle Therapeutics reported Enterprise Value of -$111.9 million as of Q3 2025, which was up 41.51% from -$191.3 million recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Enterprise Value ranged from a high of $1.4 billion in Q4 2021 and a low of -$191.3 million during Q2 2025.
  • Moreover, its 3-year median value for Enterprise Value was $260.1 million (2023), whereas its average is $262.4 million.
  • In the last 5 years, Bicycle Therapeutics' Enterprise Value surged by 448.18% in 2021 and then tumbled by 127.21% in 2025.
  • Over the past 5 years, Bicycle Therapeutics' Enterprise Value (Quarterly) stood at $1.4 billion in 2021, then crashed by 60.05% to $539.7 million in 2022, then crashed by 55.42% to $240.6 million in 2023, then tumbled by 63.78% to $87.1 million in 2024, then slumped by 116.69% to -$111.9 million in 2025.
  • Its Enterprise Value stands at -$111.9 million for Q3 2025, versus -$191.3 million for Q2 2025 and -$164.2 million for Q1 2025.